Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 18/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HSD17B3 | P37058 | 2/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.78 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.78 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Androstenedione SCHEMBL15963582 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| Androstenedione SCHEMBL9310209 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| Androstenedione SCHEMBL12367193 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| Androstenedione SCHEMBL13752932 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| Androstenedione SCHEMBL13753017 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| Androstenedione SCHEMBL11876371 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| Androstenedione SCHEMBL15369366 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| Androstenedione SCHEMBL12153462 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| Androstenedione SCHEMBL21265627 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| Androstenedione SCHEMBL15963154 | 1.00 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078142-A1 | FULLY-CONTINUOUS SYNTHESIS METHOD OF CYPROTERONE ACETATE | UNIV FUDAN (CN) | 2026-03-19 | — | — | US | claimed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | claimed |
| CN-119125361-A | Rapid detection method for 27 steroid hormones in mangrove plants | 中国科学院南海海洋研究所 | 2024-12-13 | — | — | CN | claimed |
| CN-117836004-A | Application of ST lipoid compound in preparation of nucleic acid delivery reagent and related products | 中国医学科学院基础医学研究所 | 2024-04-05 | — | — | CN | claimed |
| CN-114933624-B | Artificial synthesis method of natural product (+) -digitonin | 大连理工大学 | 2024-02-20 | — | — | CN | claimed |
| US-20230346800-A1 | REDUCTION OF THE INCIDENCE OR RECURRENCE OF BREAST CANCER IN POSTMENOPAUSAL WOMEN TREATED WITH INTRAVAGINAL SEX STEROID PRECURSOR | ENDORECHERCHE, INC. (CA) | 2023-11-02 | — | — | US | claimed |
| US-11690852-B2 | Reduction of the incidence or recurrence of breast cancer in postmenopausal women treated with intravaginal sex steroid precursor | ENDORECHERCHE. INC. | 2023-07-04 | — | — | US | claimed |
| CN-110656147-B | Biological dehydrogenation method of androstenedione C1,2 position | 湖南新合新生物医药有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115747839-A | Method for preparing 19-aldehyde-4-androstene-3,17-diketone by electrocatalytic oxidation of nickel-molybdenum oxide | 浙江工业大学 | 2023-03-07 | — | — | CN | claimed |
| US-11578096-B2 | Method for preparing 7alpha-methyl-19-aldehyde-4-androstene-3,17-dione by electrocatalytic oxidation | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2023-02-14 | — | — | US | claimed |
| EP-0072880-A1 | A composition for use in the control of ovulation of female bovines | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1983-03-02 | — | — | EP | claimed |
| EP-0008214-B1 | MICROORGANISMS AND THEIR USE IN PRODUCING ANDROST-4-ENE-3,17-DIONE | THE UPJOHN COMPANY (US) | 1982-06-02 | — | — | EP | claimed |
| US-4331657-A | IMMUNIZING AGAINST A STEROIDAL ANDROGEN OR OESTROGEN | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 1982-05-25 | — | — | US | claimed |
| US-4273872-A | TRANSFORMATION OF CHOLESTEROL TO D-4-CHOLESTERN-3-ONE IN A PARAFFINIC HYDROCARBON MEDIA CONTAINING BACTERIA | SNAMPROGETTI S.P.A. (IT) | 1981-06-16 | — | — | US | claimed |
| US-4272445-A | STEROIDS, BASIC CATALYSTS, ALKYLATION | BEECHAM GROUP LIMITED (GB) | 1981-06-09 | — | — | US | claimed |
| EP-0027829-A1 | Process for the preparation of 9-alpha-hydroxy-4-androstene-3,17-dione | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-05-06 | — | — | EP | claimed |
| US-4237220-A | Process for preparing 9α-hydroxy-4-androstene-3,17-dione | SCHERING, AKTIENGESELLSCHAFT (DE) | 1980-12-02 | — | — | US | claimed |
| US-4100027-A | Process for the preparation of 4-androstene-3,17-dione derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1978-07-11 | — | — | US | claimed |
| US-4100026-A | Process for the preparation of 4-androstene-3,17-dione derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1978-07-11 | — | — | US | claimed |
| US-3966714-A | Process for the preparation of a Δ4 -3-keto steroid 17-propiolactone | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | CYP19A1 972/4885ALDH1A1 3966/4885LMNA 3666/4885 |
| US-20260078142-A1 | FULLY-CONTINUOUS SYNTHESIS METHOD OF CYPROTERONE ACETATE | CYP17A1, CYP21A2, HSD17B2 | CYP19A1 14/4885ALDH1A1 241/4885LMNA 2995/4885 |
| US-11578096-B2 | Method for preparing 7alpha-methyl-19-aldehyde-4-androstene-3,17-dione by electrocatalytic oxidation | HSD17B1, HSD17B2, HSD17B7 | CYP19A1 18/4885ALDH1A1 74/4885LMNA 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.